Ubs Group Ag Spruce Biosciences, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Spruce Biosciences, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 13 shares of SPRB stock, worth $5. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 131,923 99.99%

Holding current value

Previous $68,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.42 - $0.59 $55,402 - $77,826	-131,910 Reduced 99.99%	13 $0
Q2 2024 Aug 13, 2024	BUY	$0.51 - $0.85 $59,215 - $98,692	116,109 Added 734.22%	131,923 $68,000
Q1 2024 May 13, 2024	BUY	$0.7 - $5.49 $10,730 - $84,156	15,329 Added 3160.62%	15,814 $12,000
Q4 2023 Feb 09, 2024	BUY	$1.04 - $2.93 $490 - $1,382	472 Added 3630.77%	485 $1,000
Q2 2023 Aug 11, 2023	SELL	$1.92 - $2.6 $1,818 - $2,462	-947 Reduced 98.65%	13 $0
Q1 2023 May 12, 2023	SELL	$1.15 - $3.17 $5,386 - $14,848	-4,684 Reduced 82.99%	960 $2,000
Q4 2022 Feb 08, 2023	SELL	$0.99 - $1.43 $1,849 - $2,671	-1,868 Reduced 24.87%	5,644 $6,000
Q3 2022 Nov 10, 2022	BUY	$1.18 - $2.19 $1,963 - $3,644	1,664 Added 28.45%	7,512 $10,000
Q2 2022 Aug 10, 2022	BUY	$1.28 - $2.23 $2,483 - $4,326	1,940 Added 49.64%	5,848 $10,000
Q1 2022 May 16, 2022	SELL	$1.85 - $4.59 $2,665 - $6,614	-1,441 Reduced 26.94%	3,908 $8,000
Q4 2021 Feb 14, 2022	BUY	$2.33 - $5.74 $12,463 - $30,703	5,349 New	5,349 $24,000
Q1 2021 May 12, 2021	SELL	$14.8 - $25.79 $70,300 - $122,502	-4,750 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$15.38 - $32.42 $73,055 - $153,995	4,750 New	4,750 $115,000

Others Institutions Holding SPRB

# of Institutions

Shares Held

15.4M

Call Options Held

16.7K

Put Options Held

1.1K

View Full List

About SPRUCE BIOSCIENCES, INC.

Ticker SPRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,560,200
Market Cap $9.42M
Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...

More about SPRB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account